

# Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2

Jana S. Huisman<sup>1,2¶</sup>, Jérémie Scire<sup>2,3¶\*</sup>, Daniel C. Angst<sup>1</sup>  
Richard A. Neher<sup>2,4</sup>, Sebastian Bonhoeffer<sup>1†</sup>, Tanja Stadler<sup>2,3†\*</sup>

<sup>1</sup> Department of Environmental Systems Science, ETH Zurich, Swiss Federal Institute of Technology, Zurich, Switzerland

<sup>2</sup> Swiss Institute of Bioinformatics, Lausanne, Switzerland

<sup>3</sup> Department of Biosystems Science and Engineering, ETH Zurich, Swiss Federal Institute of Technology, Basel, Switzerland

<sup>4</sup> Biozentrum, University of Basel, Basel, Switzerland

¶,† These authors contributed equally

\* Corresponding authors: [jeremie.scire@bsse.ethz.ch](mailto:jeremie.scire@bsse.ethz.ch), [tanja.stadler@bsse.ethz.ch](mailto:tanja.stadler@bsse.ethz.ch)

**Classification:** Biological Sciences, Population Biology

**Keywords:** Reproductive number, SARS-CoV-2, infectious disease, public health surveillance

## Abstract

The effective reproductive number  $R_e$  is a key indicator of the growth of an epidemic. Since the SARS-CoV-2 pandemic started, many methods and online dashboards have sprung up to monitor this number. However, these methods are not always thoroughly tested or are applied only to a limited geographic range. Here, we present a method for near real time monitoring of  $R_e$ , applied to epidemic data from 170 countries. We thoroughly validate the method on simulated data, and present an intuitive web interface for interactive data exploration. We show that in the majority of countries the estimated  $R_e$  dropped below 1 only after the introduction of major non-pharmaceutical interventions. For Europe, Asia, and North America we found that the implementation of non-pharmaceutical interventions was associated with reductions in the effective reproductive number. Globally, we found that relaxing non-pharmaceutical interventions did not fully revert  $R_e$  values to their original levels. Generally, our framework is useful both to inform governments and the general public on the status of the epidemic in their country, as well as a source for detailed comparison between countries and in relation to local public health policies and external covariates such as mobility, behavioural, or weather data.

## Significance statement

During the SARS-CoV-2 pandemic, governments need a way to monitor the epidemiological situation in their country. A key indicator is the effective reproductive number  $R_e$ . It describes the average number of secondary infections caused by a primary infected individual. Here, we present a method to estimate  $R_e$  from case report data. We thoroughly validate the method on simulated data, and present  $R_e$  estimates for 170 countries on an interactive web interface. We then use this method to investigate the impact of non-pharmaceutical interventions on reducing  $R_e$  worldwide. We find that the estimated  $R_e$  was significantly above 1 prior to the introduction of major non-pharmaceutical interventions, and that relaxing these interventions does not fully revert  $R_e$  estimates to their prior levels.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 1 Introduction

During an infectious-disease outbreak, such as the ongoing SARS-CoV-2 pandemic, accurate monitoring of the epidemic situation is critical to the decision-making process of governments and public health authorities. The magnitude of an epidemic, as well as its spatial and temporal infection dynamics determine the exposure risk posed to citizens in the near and long-term future, the pressure on critical infrastructure like hospitals, and the overall burden of disease to society.

The effective reproductive number  $R_e$  is a key indicator variable to describe how a pathogen spreads in a particular population [1, 2, 3]. It quantifies the average number of secondary infections caused by a primary infected individual. It also has a natural threshold value of 1, below which the epidemic reduces in size [1, 4].  $R_e$  typically changes during the course of an epidemic as a result of the depletion of susceptible individuals, changed contact behaviour, seasonality of the pathogen, or the effect of pharmaceutical and non-pharmaceutical interventions (NPIs) [1, 5, 6, 7, 8].

Different methods have been developed to estimate the effective reproductive number. They broadly fall into two categories: those based on compartmental models, e.g. [5, 9, 10], and those that count the number of secondary infections per infected individual directly, based on a time series of infection incidence, e.g. [11, 12]. We focus on the latter methods, in particular the EpiEstim method of Cori et al. [12], as they rely on only few, simple assumptions, are less prone to model misspecifications, and well-suited for near real-time monitoring of the epidemic [13].

The infection incidence based methods face the difficulty that infection events cannot be observed directly [13]. These events can only be surmised with a certain time lag, e.g. when individuals show symptoms and are tested, via contact tracing, or via periodic testing of a cohort of individuals [4]. To use these methods, one must thus employ a proxy for infection events (e.g. the observed incidence of confirmed cases, hospitalisations, deaths). This proxy is either used directly in lieu of the infection incidence, or it is used as an indirect observation to infer past infections [13]. A benefit of the infection incidence based methods is that they can be applied to multiple proxies of infection events independently, allowing for direct comparison of the inferred results for the same epidemic [6]. However, depending on the method used to infer infections from the observed incidence time series, one can also introduce biases such as smoothing sudden changes in  $R_e$  [13, 14, 15].

Several methods, software packages, and online dashboards have been developed to monitor  $R_e$  during the SARS-CoV-2 pandemic (e.g. [16, 17, 18]). A pipeline for the continuous monitoring of  $R_e$  using infection incidence based methods should include four critical steps: (i) gathering and curation of observable proxy data of infection incidence, (ii) reconstruction of the unobserved infection events, (iii)  $R_e$  estimation, and (iv) communication of the results, including uncertainty and potential biases. These are four axes that also define the differences between existing methods. During the SARS-CoV-2 epidemic, many local public health authorities have made case data publicly available. Depending on the data sources used,  $R_e$  reports span different geographical scopes, from the scale of a city, region, country, or the entire globe [17, 19, 20]. The second step, i.e. going from a noisy time series of indirect observations to an infection incidence time series, is technically the most challenging. Biases can be introduced easily, and accurately assessing the uncertainty around the inferred infection incidence is a challenge in itself [13]. For the third step, i.e. to estimate  $R_e$  from a timeline of infection events, there are ready-to-use software packages [12, 21], which produce unbiased  $R_e$  estimates along with an estimate of the uncertainty resulting from this step. Finally, the communication of results to the general public and decision makers is essential, but is often overlooked.

We present a pipeline, together with an online dashboard, for near real-time monitoring of  $R_e$ . We use publicly available data gathered by different public health authorities. Wherever possible, we show results obtained from different types of case reports (confirmed cases, hospitalisations or death). This allows comparison across observation types and hence a better assessment of the validity of the estimates. Results are updated daily, and can be found on <https://ibz-shiny.ethz.ch/covid-19-re/>.

51 Because  $R_e$  estimates reflect changes in virus transmission dynamics, they can be used to as-  
52 sess the impact of public health interventions. Prior work on the relative impact of specific non-  
53 pharmaceutical interventions on  $R_e$  has shown conflicting results [8, 22, 23, 24, 25, 26]. These  
54 differences can be attributed mostly to different model formulations [24, 27], including differing as-  
55 sumptions on the independence of NPIs [27], differing timescales over which the effect of the NPI  
56 was analysed [8, 25], whether the time point of the NPI was assumed fixed or allowed to vary [26],  
57 and differing geographical scope.

58 There is a need to address whether the strength of measures and the speed of their implementation  
59 resulted in a larger and faster decrease in the  $R_e$ , and specifically whether highly restrictive lock-  
60 downs were necessary to reduce  $R_e < 1$ . Further, it remains unclear how the impact of interventions  
61 differed across time and geographical regions. We add to this debate by using our global  $R_e$  esti-  
62 mates across timescales that include the lifting of many NPIs. While we cannot determine causal  
63 relationships, we use our method to assess likely associations.


## 64 2 Results

65 **A new pipeline to estimate the effective reproductive number of SARS-CoV-2.** We have de-  
66 veloped a pipeline to estimate the time-varying effective reproductive number of SARS-CoV-2 from  
67 observed COVID-19 incidence time series (see Materials and Methods). We build upon the existing  
68 EpiEstim method [12] to estimate  $R_e(t)$  from a time series of infection incidence. To infer the infec-  
69 tion incidence from a time series of (noisy) observations, we extended the deconvolution method by  
70 Goldstein *et al.* to deal with partially observed data and time-varying delay distributions [13, 14].  
71 To reduce numerical artefacts resulting from the noisy nature of these observations, we smooth the  
72 data prior to deconvolution. We take into account uncertainty in the observation process using a  
73 bootstrap procedure, and in the  $R_e$  estimation using the 95% highest posterior density intervals from  
74 EpiEstim. As observed incidence data we use COVID-19 confirmed case data, hospital admissions,  
75 and deaths (with type specific delay distributions, see Materials and Methods).

76 **Validation on simulated data.** The method was validated with simulations of several epidemic  
77 scenarios (Materials and Methods section 4.5). For each scenario, we specified an  $R_e$  time-series,  
78 from which we simulated infection and observation incidence. Then, we used our method to infer  
79 the infection incidence and  $R_e$  from the observation incidence, and compared to the true underlying  
80  $R_e$  values (Fig. 1A). The specified  $R_e$  trajectories were parametrised in a piecewise linear fashion,  
81 where we fixed the plateau values for  $R_e$  and the time-points at which the trajectory changed slope.  
82 To mimic the course of the epidemic observed in many European countries in spring and summer  
83 2020 [28], we started with  $R_e$  values around 3, then dropped to a value below 1 (the ‘initial decrease’),  
84 to subsequently rise slightly above 1 for some time (Fig. 1).

85 The results show that our method allows accurate monitoring of the effective reproductive number  
86 across the entire length of the time series (Fig. 1B; metrics described in Materials and Methods  
87 section 4.5). The low root mean square error (RMSE) indicates that our estimates closely track the  
88 true  $R_e$  value. In the simulated trajectories, the slope of the initial decrease can be correctly inferred,  
89 although the relative error is greater for steeper slopes (Slope error). More importantly, we correctly  
90 infer whether  $R_e$  is significantly above or below 1 for 95% of the time series (Correct  $R > 1/R < 1$ ),  
91 and across all simulations we miss the date of the  $R = 1$  crossing by at most 3 days ( $R = 1$  difference;  
92 calculated between the  $R_e$  point estimate and the true  $R_e$ ).

93 The minor misestimation of the slope is primarily due to the smoothing step included in our deconvol-  
94 ution algorithm. However, the inclusion of smoothing greatly improves our performance across more  
95 realistic scenarios with daily or weekly observation noise (Supplemental Fig. S1). With smoothing,  
96 the performance of our method is mostly independent of the amount of observation noise (Supple-  
97 mental Fig. S2). When the mean of the delay distribution between infection and case observation  
98 is misspecified, we can still determine the shape of the  $R_e$  curve, but do misestimate when  $R_e = 1$



**Figure 1: (A) Example simulation (coloured lines) and estimation (black lines).** The left panel shows the specified  $R_e$  trajectory (yellow line) with five plateaus  $R_e = (3.5, 0.5, 1.2, 0.95, 1.1)$  and the estimated  $R_e$  trajectory. The right panel shows the simulated infections (in green; initial infection incidence  $I_0 = 10$ ), and the case observations (in blue) simulated from those infections. The infection incidence inferred from the case observations is shown in black. The trajectory shape mimics the course of the epidemic observed in many European countries, which started with an  $R_e \sim 3$ , then dropped to a low value below 1 (the ‘initial decrease’), to subsequently oscillate around 1 for some time. **(B) Performance of our method on simulated scenarios.** From top to bottom, left to right, we show: (i) the normalised root mean squared error (RMSE), (ii) the error of the slope of the first decrease, (iii) the delay of the mean crossing  $R_e = 1$ , (iv) the fraction of time points for which we correctly infer that  $R_e$  is significantly above or below one, (v) the coverage of the true  $R_e$  value. These metrics are further described in Materials and Methods section 4.5. In the scenarios we varied the initial  $R_e$  level ( $R_1$ ; point shape), the time of the first descent ( $t_3$ ; point colour), and the number of initial infections ( $I_0 \in \{10, 100, 1000\}$ ; not indicated separately as it determines the peak infection incidence directly). In these simulations a shorter  $R_e$  time series was used than in panel (A), with three plateaus:  $R_2 = 0.5, R_3 = 1.2$ .

99 (Supplemental Fig. S3). Further model misspecifications, such as a wrong generation time interval,  
 100 have been investigated by Gostic et al. [13].

101 The fraction of the  $R_e$  time-series where the true value of  $R_e$  falls within our estimated confidence  
 102 intervals (the ‘coverage’), decreases strongly for larger overall infection incidence. This indicates  
 103 that the confidence intervals are too narrow for large case numbers. This result is consistent across

104 all scenarios, independent of the slope of the initial decrease (Fig. 1B) or the delay distribution  
105 used (data not shown). We are improving the bootstrapping method further to account for this vari-  
106 ance.

107 Our method clearly outperforms the common approach of using a fixed delay to infer the infection  
108 incidence time series (Supplemental Fig. S5). Our ability to allow for empirical, time-varying dis-  
109 tributions in the estimation also slightly improves the estimated  $R_e$  (Supplemental Figs. S4a, S4b),  
110 especially when strong time variation is present.

111 **Monitoring  $R_e$  during the COVID-19 pandemic.** We apply this  $R_e$  estimation method to COVID-19  
112 case data from 170 countries (Fig. 2). All estimates are updated daily and made publicly available on  
113 an online dashboard <https://ibz-shiny.ethz.ch/covid-19-re/> (results available for download).  
114 For most countries, we include multiple observation sources, such as daily incidence of COVID-19  
115 cases and deaths, and, when available, hospitalisation incidence.


116 The online app allows for comparison through time within a single country, between multiple obser-  
117 vation traces, or between multiple countries. The data download further allows users to put these  
118 estimates in relation to external covariates such as mobility, weather, or behavioural data. The map  
119 view enables comparison across larger geographical areas and additionally reports the cases per  
120 100'000 inhabitants per 14 days.

121 **Fine-scale data allows fine-scale analysis: the example of Switzerland** When detailed epi-  
122 demiological data about individual cases (i.e. line lists) is available, we can increase the precision of  
123 our method by relaxing two assumptions: (i) distributions of delays between infection and observa-  
124 tion do not change through time and (ii) outbreaks occur in a well-mixed homogeneous population  
125 at the country-level. In particular, we collaborated with the Federal Office of Public Health (FOPH) in  
126 Switzerland to further refine the monitoring of the Swiss SARS-CoV-2 epidemic.

127 The FOPH line list data contains information on the delays between onset of symptoms and report-  
128 ing (of a positive test, hospitalisation or death) for a significant fraction of the reported cases. We  
129 estimate the time-varying empirical delay distribution from this data and use it as input to the de-  
130 convolution step, instead of estimates of these delays from the literature (for details see Materials  
131 and Methods section 4.2). The delay distribution is thus tailored to the specifics of the Swiss popu-  
132 lation and health system. Moreover, each distribution varies through time and thus reflects changes  
133 caused by e.g. improved contact tracing or overburdened health offices (see Fig S6; Supplementary  
134 Discussion). Whenever available in the FOPH line list, we use the symptom onset date of patients  
135 as the date of observation and thus only deconvolve the incubation period to obtain a time series of  
136 infection dates. The effect of these modifications is relatively minor in most parts of the estimated  $R_e$   
137 curve (see Fig. S7), yet the difference between  $R_e$  point estimates for a particular day can be as big  
138 as 20%.

139 Using FOPH data on the fraction of cases infected abroad, we can correct our  $R_e$  estimate for im-  
140 ports to reflect only local transmission. This is especially important in phases during which the local  
141 epidemic is seeded from abroad, and local transmission occurs at a low rate relative to case impor-  
142 tation (Fig. S8). Since we do not have data on the number of cases infected in Switzerland and then  
143 "exported" to other countries, we cannot correct for exports. Thus, the estimated  $R_e$  value corrected  
144 for imports is a lower bound for the  $R_e$  estimate which would be obtained if we could account for the  
145 location of infection of all cases detected in Switzerland or exported out of the country.

146 **In the majority of countries the critical threshold  $R=1$  was crossed only after the implemen-**  
147 **tation of nationwide lockdowns.** With our method, we can now assess the association between  
148 non-pharmaceutical interventions (NPIs) and the effective reproductive number  $R_e$ . We selected  
149 20 European countries for which the reported data was free of major gaps or spikes (as these are



**Figure 2: Example panels from the online dashboard. (A)** Swiss cases,  $R_e$  estimates, timeline of non-pharmaceutical interventions (NPIs), and stringency index. **(B)** World map of incidence per 100'000 inhabitants over the last 14 days. **(C)** Comparison of  $R_e$  estimates across a handful of countries, with timelines of stringency indices. All panels were extracted on Nov. 13 2020. Dashboard url: <https://ibz-shiny.ethz.ch/covid-19-re>.

150 indicative of low-quality reporting), and for which we could estimate  $R_e$  prior to the nationwide im-  
 151 plementation of a lockdown. The dates of interventions were extracted from news reports (sources  
 152 listed in Supplementary Table S2), and 'lockdown' taken to refer to stay-at-home orders of differing  
 153 intensity. Of the countries investigated, all except Sweden implemented a lockdown (19/20). We  
 154 estimated that  $R_e$  was significantly above one prior to the lockdown measures in nearly all countries  
 155 with a lockdown (17/19; Table 1). Only Denmark, which had a complex outbreak consisting of two  
 156 initial waves, had an estimated  $R_e$  significantly below one prior to this date. We showed on simu-  
 157 lated data that our method estimates the date of the  $R_e = 1$  threshold crossing with up to 3 days  
 158 delay. Accounting for these 3 days does not change our results (Table 1). The results are also re-  
 159 markably consistent across the different observation types (Supplementary Table S1). However, the  
 160 confidence intervals tend to be wider for the estimations based on the death incidence because the  
 161 number of deaths is much smaller than the number of cases, and the relative noise in observations  
 162 tends to be higher.


163 To consider this question for countries outside of Europe, we used the stringency index (SI) of the  
 164 Blavatnik School of Government [29] to describe the public health response in different countries  
 165 (Fig. 3a). This is a compound measure describing e.g. whether a state has closed borders, schools,  
 166 or workplaces. For example, a country with widespread information campaigns, partially closed bor-  
 167 ders, closed schools, and a ban on public events and gatherings with more than 10 people would

Country	Lockdown	Date that $R < 1$	Time until $R < 1$
Austria	16-03	21-03 [21-03, 22-03]	5 days
Belgium	18-03	31-03 [30-03, 02-04]	13 days
Denmark	18-03	<b><math>\leq 10-03</math> [<math>&lt; 10-03</math>, 11-03]</b>	-8 days
Finland	16-03	03-04 [01-04, 06-04]	18 days
France	17-03	27-03 [27-03, 28-03]	10 days
Germany	22-03	26-03 [26-03, 27-03]	4 days
Ireland	27-03	09-04 [08-04, 10-04]	13 days
Italy	10-03	18-03 [18-03, 19-03]	8 days
Netherlands	23-03	01-04 [26-03, 04-04]	9 days
Norway	14-03	23-03 [22-03, 24-03]	9 days
Poland	25-03	03-04 [02-04, 17-04]	9 days
Portugal	16-03	29-03 [28-03, 30-03]	13 days
Romania	16-03	06-04 [02-04, 30-04]	13 days
Russian Federation	30-03	05-05 [04-05, 05-05]	36 days
Slovenia	20-03	24-03 [ <b><math>\leq 14-03</math>, 28-03</b> ]	4 days
Spain	14-03	18-03 [02-02, 18-03]	4 days
Sweden		<b>19-04 [01-04, 21-04]</b>	
Switzerland	17-03	22-03 [21-03, 22-03]	5 days
Turkey	21-03	09-04 [08-04, 09-04]	19 days
United Kingdom	24-03	31-03 [30-03, 31-03]	7 days

**Table 1: The date that  $R_e < 1$  for the first time.** Based on news reports, we report when a country implemented stay-at-home orders (a ‘lockdown’). We determined when the  $R_e$  estimate and its confidence intervals first dropped below 1. Of the investigated countries that implemented a nationwide lockdown, only two (Denmark, Slovenia) had  $R_e$  estimates that included or were below one before a nationwide lockdown was implemented. ‘Time until  $R < 1$ ’ indicates the number of days between the lockdown and the date that the mean  $R_e < 1$ .

168 have an SI slightly above 50. As reference date, we determined when a country first exceeded a  
169 stringency index of 50 ( $t_{SI50}$ ). Then, we asked whether the estimated  $R_e$  was significantly above 1  
170 prior to the reference date, where we again excluded countries without  $R_e$  estimates before the refer-  
171 ence date. Out of 39 countries world-wide which fulfilled the criteria for inclusion (list in Supplement  
172 8.3), 28/39 countries were significantly above 1 prior to  $t_{SI50}$ . As an additional analysis, for each day,  
173 we calculated the change of SI within the past 7 days. We used the day with the maximal change as  
174 the new reference date ( $t_{max}$ ). This analysis yielded very similar results with 36/50 countries signif-  
175 icantly above one before  $t_{max}$  (Supplement 8.3). Accounting for the 3 days of possible delay, 31/39  
176 countries were still above 1 before  $t_{SI50}$  (significantly above for 25/39 countries), and 40/50 countries  
177 before  $t_{max}$  (significantly above for 33/50).

178 **A strong government response is associated with a faster decrease in  $R_e$ .** Next, we asked  
179 whether the slope of  $R_e$  on the reference date  $t_{SI50}$  (one-day change) is associated with the deci-  
180 siveness of the government response, as measured by the change in the stringency index the week  
181 prior. In Europe, larger changes in the SI prior to  $t_{SI50}$  were significantly associated with stronger  
182 decreases in the estimated  $R_e$  on the reference date ( $p = 0.04$ , adjusted  $R^2 = 0.18$ , Fig. 3(b); 19  
183 countries). The same trend was found at a global scale, though no longer significant (Fig. S9; 40  
184 countries). However, this does not mean that the SI at lockdown is a predictor for the time until  $R_e$   
185 is below 1 ( $p = 0.9$ , Fig. S10(a)). This time instead was better predicted by the estimated  $R_e$  on the  
186 day of lockdown ( $p = 0.03$ , adjusted  $R^2 = 0.2$ , Fig. S10(b)). Finally, there is no significant association  
187 between higher maximum SI during lockdown and a lower minimum  $R_e$  attained during that time  
188 ( $p = 0.14$ , Fig. S11).




**Figure 3: The association between non-pharmaceutical interventions and  $R_e$  during the first phase of the epidemic. (a)** Estimated  $R_e$  (top) and government stringency index (bottom) for India, South Africa, Switzerland, and the United States of America. **(b)** Relation between the slope of the  $R_e$  estimates on  $t_{SI50}$  and the increase in the stringency index over the 7 days prior to  $t_{SI50}$  for 19 European countries. The countries are indicated by their ISO3 country code.

189 **Insights into continent-specific responses to NPIs.** To investigate the association between changes  
 190 in government stringency and changes in  $R_e$  in more depth, we extended our analysis until Novem-  
 191 ber 10th and included both the implementation and lifting of NPIs (increases and decreases in strin-  
 192 gency). For each week and country, we determined whether the stringency index changed, and if  
 193 so, what the effect was on  $R_e$  after 7 days. If NPIs are working as expected, increases in stringency  
 194 should be associated with a decrease in  $R_e$  and vice versa. We do find this for increases in strin-  
 195 gency e.g in Europe (blue bars, Fig. 4a), but decreases in stringency have a more varied effect on  
 196  $R_e$  estimates on all continents (red bars, Fig. 4a). This may be modulated by temporal differences in  
 197 when NPIs were implemented or lifted (Fig. 4b).

198 For North America, Asia, and Europe, an increase in stringency was significantly more associated  
 199 with a subsequent reduction in the estimated effective reproductive number  $R_e$  than a reduction in  
 200 stringency was (permutation test randomising SI increase/decrease associated with the estimated  
 201 change in  $R_e$ ,  $\alpha = 0.05$ , 6-way Bonferroni correction). For these continents, increases in stringency  
 202 also resulted in a stronger absolute change than decreases in stringency (permutation test randomis-  
 203 ing SI increase/decrease associated with the estimated change in  $R_e$ ,  $\alpha = 0.05$ , 6-way Bonferroni  
 204 correction). This suggests that reversing non-pharmaceutical interventions had a very different effect  
 205 than introducing them. For the continents Africa, South America, and Oceania no significant differ-  
 206 ence could be detected between the distributions of estimated  $R_e$  changes after implementation or  
 207 lifting of NPIs.

208 We further repeated this analysis for 8 individual indices that make up the SI compound index sep-  
 209 arately. Continents differ substantially in which indices showed signal that an increase in stringency  
 210 was significantly more associated with a subsequent reduction in  $R_e$  than a reduction in stringency.  
 211 Four index-continent pairs showed a significant effect: school closing and closing public transport in  
 212 Europe, cancelling public events in South America, and stay at home requirements in North America  
 213 (as determined by permutation test randomising SI increase/decrease associated with the estimated  
 214 change in  $R_e$ ,  $\alpha = 0.05$ , 6\*8-way Bonferroni correction; Supplementary Table S3). Similar, yet non-  
 215 significant, trends were observed for some of the other index-continent pairs. We further tested  
 216 whether there was a linear relationship between the change in stringency of the individual indices  
 217 and the resulting estimated change in  $R_e$  (Supplementary Fig. S12, Table S4). The highest  $R^2$  values  
 218 were found for the index-continent pairs also identified in the previous analysis.





**Figure 4: The association between non-pharmaceutical interventions and changes in  $R_e$ .** (a) Histogram of the estimated 7-day change in  $R_e$  following the implementation (blue, above x-axis) or lifting (red, below x-axis) of NPIs in a given week. The height of the bars is given by the number of countries with this observation, coloured by the change in stringency index that week. If NPIs are working as expected, we would expect an increase in stringency (i.e. bars above the x-axis) to be more associated with a decrease in  $R_e$  (shifted to the left) and bars below the x-axis to be shifted more to the right. Note, scales differ between the continents. (b) Strength of NPI changes through time, coloured by their effect on  $R_e$  (increase is blue, a decrease red). Here, the height of bars is given by the summed change in the stringency index over all countries that week. If NPIs are working as expected, we would expect bars above the x-axis (i.e. an increase in stringency) to be more red (i.e. associated with a decrease in estimated  $R_e$ ) and bars below the x-axis to be more blue.

### 219 3 Discussion

220 We have developed a pipeline to monitor the effective reproductive number  $R_e$  of SARS-CoV-2 in  
 221 near real-time, and validated our estimates with simulations. We showed that the inferred  $R_e$  curve  
 222 can be slightly over-smoothed on simulated data, but that this is a necessary compromise given the  
 223 inherent noisiness and sometimes low quality of real data. Overall, we show that the relative error in  
 224 the  $R_e$  estimates is small. In particular, we can detect when  $R_e$  crosses the critical threshold of 1,  
 225 which is important to an informed public health response.

226 During the ongoing SARS-CoV-2 pandemic,  $R_e$  estimates are of interest to health authorities, politi-  
 227 cians, decision makers, the media and the general public. Because of this broad interest and the criti-  
 228 cal importance of  $R_e$  estimates, it is crucial to communicate both the results as well as the associated  
 229 uncertainty and caveats in an open, transparent and accessible way. This is why we display daily up-

230 dated results on an online dashboard, accessible at <https://ibz-shiny.ethz.ch/covid-19-re/>.  
231 The dashboard shows  $R_e$  estimates in the form of time series for each included country or region,  
232 and a global map containing the latest  $R_e$  estimates and normalised incidence. For a number of Eu-  
233 ropean countries, we also display a timeline of the implementation and lifting of non-pharmaceutical  
234 interventions (NPIs). For all countries, we display a timeline of the stringency index of the Blavatnik  
235 School of Government.

236 A unique advantage of the monitoring method we have developed is the parallel use of different types  
237 of observation data, all reflecting the same underlying infection process [6]. Wherever we have data  
238 of sufficient quality, we estimate  $R_e$  separately based on confirmed cases, hospitalisations and death  
239 reports. The advantages and disadvantages of the different observation types are discussed in the  
240 Supplementary discussion 6.1. Comparing estimates from several types of data is a powerful way  
241 to evaluate the sensitivity of the results to the type of observations they were derived from. More  
242 generally, the method would be applicable to any other type of incidence data, such as admissions  
243 to intensive care units or excess death data. The potential limitations of our  $R_e$  estimation method  
244 are discussed in detail in the Supplementary Discussion 6.2.

245 The decision to implement, remove or otherwise adjust measures aimed at infection control will be  
246 informed by epidemiological, social and economic factors [30]. We can aid this decision making  
247 process by investigating the association between adjustments of public-health measures and the  
248 estimated  $R_e$ .

249 The merits of nation-wide lockdowns have been heavily discussed, both in the scientific literature as  
250 well as in the public sphere [8, 25, 23, 24, 31]. In particular, analyses showing that  $R_e$  estimates had  
251 dropped below 1 before the strictest measures were enforced were frequently used to claim that a  
252 lockdown was not necessary [31]. We showed that this argumentation is flawed: for 17 out of 20  
253 European countries, we found that the estimated  $R_e$  was significantly above 1 prior to the lockdown  
254 in spring.

255 For this first epidemic wave, we further investigated the link between the strength of NPIs imple-  
256 mented and the concurrent decrease of  $R_e$ . There was a trend that countries with a strong increase  
257 in stringency prior to the reference date  $t_{SI50}$  saw a faster decrease in pathogen transmission on that  
258 day. However, this analysis focused only on the estimated one-day change in  $R_e$  around the onset of  
259 the lockdown. We did not find that the strength of the government response significantly determined  
260 the time it takes to bring  $R_e < 1$ , nor the value of  $R_e$  during a lockdown. To investigate these points  
261 conclusively, further analyses are needed that are beyond the scope of this manuscript.

262 Extending our analysis to data up until Nov. 10, we find differences between continents in the ef-  
263 fect of NPIs on  $R_e$ . This could reflect differences in the speed with which lockdowns were put into  
264 practice [26], the de-facto lockdown stringency, or socio-cultural aspects [30, 32]. It is often argued  
265 that, especially in countries with a large informal business sector, there may be a difference between  
266 the official containment measures and those adhered to or implemented de-facto [32]. However, for  
267 continents where we find no significant effect of NPI implementation, this could also be because the  
268 majority of NPIs were implemented at a time for which we could not estimate changes in  $R_e$ . Many  
269 African countries implemented early and strict government responses, often prior to the first detected  
270 cases. These are thought to have delayed the virus in establishing a foothold on the continent [32].  
271 Since we cannot estimate  $R_e$  without cases, such early response would not be seen to reduce  $R_e$   
272 in our analyses.

273 Importantly, our analysis suggests that reversing non-pharmaceutical interventions had a very dif-  
274 ferent effect than introducing them. This could be because the situation is not fully reverted: due  
275 to increased public awareness, testing, contact tracing, and quarantine measures still in place. In  
276 addition, the epidemic situation - in terms of number of infected individuals - is likely different when  
277 measures are implemented or lifted.

278 Our analysis could be confounded by other economic, social, and psychological factors motivating  
279 the implementation or release of measures. With the current stringency measures we can not ac-

280 count for diversity in adherence to NPIs across geographic regions and through time. Cultural norms,  
281 defiance towards public authorities, "lockdown fatigue", and economic pressures are all among the  
282 factors that may determine whether NPIs are in fact adhered to. In addition, there is increasing ev-  
283 idence that weather may be a factor influencing  $R_e$  through its effect on people's behaviour as well  
284 as properties of the virus [33]. In the future, our tools to quantify  $R_e$  could be used to explore asso-  
285 ciations of these many factors with  $R_e$ , with the aim of identifying minimal sets of factors ensuring an  
286  $R_e < 1$  for particular locations.

## 287 Acknowledgements

288 We thank the Federal Office of Public Health Switzerland for access to their line list data, and mem-  
289 bers of the modelling group of the Swiss National Covid-19 science task force for helpful discussions.  
290 We thank Marloes Maathuis for her feedback to the paper, discussions, and follow-up work on the  
291 bootstrapping methods together with Jinzhou Li. We thank Jūlija Pečerska for her help in finding  
292 governmental datasets on COVID-19. JSH was funded by the NRP72 SNF grant (407240-167121)  
293 awarded to SB and TS. SB and TS thank ETH Zurich for funding.

### 294 3.1 Author contributions

295 J.S.H, J.S, S.B, T.S designed research; J.S.H, J.S, D.C.A, R.A.N contributed new reagents or analytic  
296 tools; J.S.H, J.S performed research; J.S.H, J.S analyzed data; and J.S.H, J.S wrote the paper. All  
297 authors critically reviewed and approved the paper.

## 298 4 Materials and Methods

### 299 4.1 EpiEstim

300 The method presented here builds upon the  $R_e$  estimation method developed by Cori *et al.* [12],  
301 implemented in the EpiEstim R package. This method estimates  $R_e(t)$  from a time series of infection  
302 incidence, we summarise its details below.

Disease transmission is modelled with a Poisson process. At time  $t$ , an individual infected at time  $t - s$  causes new infections at a rate  $R_e(t) \cdot w_s$ , where  $w_s$  is the value of the infectivity profile  $s$  days after infection. The infectivity profile sums to 1, and can be approximated by the serial interval distribution [12]. The expected infection incidence  $I_t$  at time  $t$  is thus:

$$E(I_t) = R_e(t) \sum_{s=1}^t I_{t-s} w_s \quad (1)$$

and the likelihood of the incidence  $I_t$  is given by:

$$P(I_t | I_0, \dots, I_{t-1}, w_t, R_e(t)) = \frac{(R_e(t) \Lambda_t)^{I_t} e^{-R_e(t) \Lambda_t}}{I_t!}, \quad (2)$$

$$\text{where } \Lambda_t = \sum_{s=1}^t I_{t-s} w_s. \quad (3)$$

303 The  $R_e(t)$  inference is performed in a Bayesian framework, and an analytical solution can be derived  
304 for the posterior distribution of  $R_e(t)$  (see [12]; Web Appendix 1). We choose a gamma distributed  
305 prior on  $R_e(t)$  with mean 1, and standard deviation 5.

## 306 4.2 Deconvolution

307 To recover the non-observed time series of infection incidence, we deconvolve the observed time  
308 series of COVID-19 case incidence with a delay distribution specific to the type of case detection  
309 (case confirmation, hospital admission, death).

We extended the deconvolution method of Goldstein *et al.* [14], which is itself an adaptation of the Richardson-Lucy algorithm. Formally, the deconvolution infers an infection incidence time series  $(\lambda_1, \dots, \lambda_N)$  from a time series of observed cases  $(D_K, \dots, D_N)$ , with  $K \geq 1$ .  $D_i$  indicates the number of observed cases on day  $i$ . Let  $m_l^j$  be the probability that an infection on day  $j$  takes  $l$  days to be detected. For any  $k < 0$  and any  $l$ ,  $m_l^k = 0$ . If no line list data is available  $m_l^j = m_l$ , and no time-variation of the delay distribution is assumed. Let  $q_j$  be the probability that an infection that occurred on day  $j$  is observed during the time-window of observations, between days  $K$  and  $N$ . Then:

$$q_j = \sum_{l=K-j+1}^{N-j} m_l^j. \quad (4)$$

Let  $E_i$  be the expected number of observed cases on day  $i$ , for a given infection incidence  $(\lambda_k)$ :

$$E_i = \begin{cases} \sum_{j=1}^i \lambda_j m_{i-j}^j & \text{for } i \geq K \\ 0 & \text{for } 0 < i < K. \end{cases} \quad (5)$$

The Richardson-Lucy algorithm uses expectation maximisation to find a final infection incidence estimate, which has the highest likelihood of explaining the observed case time series. To do so, it starts from an initial guess of the infection incidence time series  $\Lambda^0 = (\lambda_1^0, \dots, \lambda_N^0)$ , and updates the estimate in each iteration  $n$  according to the following formula:

$$\lambda_j^{n+1} = \frac{\lambda_j^n}{q_j} \cdot \sum_{i=K}^N \frac{m_{i-j}^j D_i}{E_i^n}. \quad (6)$$

The iteration proceeds until a termination criterion is reached. Here, we follow Goldstein *et al.* and iterate until the  $\chi^2$  statistic drops below 1 [14], or 100 iterations have been reached:

$$\chi^2 = \frac{1}{N - K + 1} \sum_{i=K}^N \frac{(E_i^n - D_i)^2}{E_i^n}. \quad (7)$$

310 Convergence is typically fast and the stopping criterion based on the  $\chi^2$  statistic is reached in a few  
311 iterations. Due to the smoothing prior to deconvolution, this was the case for nearly all empirical data  
312 we analyzed. In some cases, e.g. when the observed incidence is very noisy, convergence can be  
313 slower and the threshold of 100 iterations can be reached. For 4/170 countries, convergence was  
314 not reached in 100 iterations: China, Ecuador, Equatorial Guinea and Peru all showed strong spikes  
315 in reporting which obstructed the deconvolution.

316 For the initial estimate of the incidence time series  $\Lambda^0$ , we shift the observation time series backwards  
317 in time by the mode of the delay distribution  $\mu$  [14]. However, this leaves a gap of unspecified  
318 values at the start and end of the time series  $\Lambda_0$ . Contrary to Goldstein *et al.*, we augment the  
319 shifted time series with the first observed value ( $D_K$ ) on the left, and with the last observed value  
320 ( $D_N$ ) on the right, to avoid initialising with a zero-value anywhere. If a day is initialised with zero  
321 incidence, it will also have zero incidence in the final estimate (compare equation 6), which would  
322 be a potential source of bias. We have compared several ways to pad the shifted observed time  
323 series for the initialisation step, and determined that augmentation with non-zero integers equal to the  
324 edge values is enough for the deconvolution to converge to the true distribution (see Supplementary  
325 Fig. S13).

326 We note that this Richardson-Lucy deconvolution algorithm accounts for ‘right truncation’, i.e. not all  
327 infections that have occurred are observed within the given observation time window (due to delay  
328 until symptoms/reporting), through the  $q_j$  indices.

329 **Use of line list data** When a line list is available, the time variation of delays between symptom  
330 onset and observation can be taken into account directly during the deconvolution step. This leads  
331 us to perform the deconvolution in two separate steps: first with the time-varying empirical onset-to-  
332 observation distributions, and then with the constant-through-time incubation period distribution. For  
333 those cases where symptom onset data is available, we only deconvolve with the incubation period  
334 distribution.

335 The  $(m_0^j, \dots, m_K^j)$  time-varying delay distributions from onset of symptoms to observation are deter-  
336 mined as follows: for each date  $j$ , at least 300 of the most recent recorded delays between symptom  
337 onset and observation, with onset date before  $j$ , are taken into account. To avoid biases caused by  
338 the intensity of testing and reporting varying throughout the week, recorded delays are included in  
339 full weeks going in the past, until at least 300 delays are included.

340 As the incidence data is right-truncated, we have to fix the reporting delay distributions  $m_i^j$  at some  
341 point, or they would be downward biased for infection dates close to the present. Let  $(m_0^0, \dots, m_K^0)$   
342 be the overall empirical delay distribution (aggregated over the entire window of observations) and  
343  $n$  the 99<sup>th</sup> percentile of this distribution ( $n$  is the smallest integer for which  $\sum_{i=1}^n m_i^0 \geq 0.99$ ). For  
344 all infection dates  $z$  such that  $M - z < n$ ,  $M$  being the index of the last available data point, we fix  
345  $(m_0^z, \dots, m_K^z)$  to be equal to  $(m_0^{M-n}, \dots, m_K^{M-n})$ .

### 346 4.3 Noise and uncertainty in the case observations

347 To reduce the influence of weekly patterns in case reporting data, as well as reporting irregularities,  
348 we smooth the observed incidence data prior to deconvolution. To smooth the incidence data, we  
349 use local polynomial regression fitting (LOESS) with 1st order polynomials and tricubic weights.  
350 The smoothing parameter alpha is set such that we always include 21 days of data in the local  
351 neighbourhood of each point. At the edges, the weights drop to 0 and less points are taken into  
352 account in total [34]. After smoothing, we normalise to the original total number of cases.

353 To reflect uncertainty in the observation process, we bootstrap the observed incidence data 50 times,  
354 prior to smoothing, deconvolution, and  $R_e$  estimation. The bootstrapping process here consists of  
355 sampling reported cases with replacement from the original case data (with equal probability per  
356 case), until a resampled time series with the same number of cases as the original one is obtained.  
357 This likely underestimates the total uncertainty because it does not take into account that some cases  
358 may be correlated, e.g. by belonging to the same transmission chain. A common way to circumvent  
359 this problem would be to use a (moving) block bootstrap method. We are working to implement this  
360 into our pipeline.

361 The  $R_e$  estimate reported for day  $T$  summarises the average estimated  $R_e$  over a 3-day period ending  
362 on day  $T$ . We report the median of the 50  $R_e$  posterior distributions obtained, as well as the median  
363 of the 95% uncertainty interval boundaries. In addition, we provide step-wise estimates of  $R_e$ . In  
364 this step-wise analysis,  $R_e$  is assumed to be constant on a number of intervals spanning the entire  
365 epidemic time window. These intervals are bounded by dates at which public health interventions  
366 were implemented, altered, or lifted.

### 367 4.4 Data

368 We gathered case incidence data directly from public health authorities. Whenever accessible, we  
369 rely on data from local authorities. Otherwise, we default to the data of the European Centre for  
370 Disease Control (ECDC) [35]. A table summarising the incidence data sources is available in Sup-  
371 plementary File S1. Information on the start and end of interventions, or major changes in testing

372 policy, were obtained from media reports and the websites of public health authorities. The strin-  
373 gency index of the Blavatnik School of Government was accessed from their publicly available github  
374 repository [29].

375 We parametrised the discretised infectivity profile  $w_s$  using COVID-19 serial interval estimates from  
376 the literature [36], i.e. a gamma distribution with a mean of 4.8 days, and a standard deviation (SD) of  
377 2.3 days. For a review of serial interval estimates published in the literature, see Griffin et al. [37]. The  
378 incubation period is parametrised by a gamma distribution with mean 5.3 days and SD 3.2 days-[38].  
379 For countries for which we do not have access to line list data, i.e. all except Switzerland, Germany  
380 and Hong Kong at the time of writing, we assume delays from symptom onset to observation to be  
381 gamma-distributed, see table 2 for parameters.

Delay	Mean (days)	SD (days)	Reference
Onset of symptoms to case confirmation	5.5	3.8	[39]
Onset of symptoms to hospital admission	5.1	4.2	[40]
Onset of symptoms to death	15.0	6.9	[38]

**Table 2: Delay distribution assumed for each observation type.**

382 For Switzerland, Germany and Hong Kong, we use line lists to build time-varying empirical distribu-  
383 tions on delays between symptom onset and case confirmation, hospitalisation or death. During the  
384 deconvolution step we use the empirical delay distribution of the last 300 recorded cases prior to the  
385 infection date. Moreover, for the fraction of cases for which the date of onset of symptoms is known,  
386 we use the onset date directly instead of deconvolving a delay from onset to reporting, allowing for  
387 more precise estimation of the infection date. For Switzerland, line lists contain information on which  
388 cases were infected abroad. By considering imported cases and locally-transmitted cases separately  
389 in the deconvolution step, we obtain two separate time series, one for local infections and one for  
390 imported infections.

## 391 4.5 Simulations

392 In the simulations, we first simulate a time series of infections and corresponding case observations  
393 from a specified piecewise linear  $R_e$  trajectory. Then, we estimate  $R_e$  from these observations us-  
394 ing our method: deconvolution to infer the infection time series, followed by EpiEstim to estimate  
395  $R_e$ .

396 To assess a range of scenarios, we parametrise  $R_e$  as a piecewise linear trajectory, where we fix  
397 the plateau values for  $R_e$  and the time-points at which the trajectory changes slope. Assuming  $I_0$   
398 infected individuals on the first day, the infection incidence is simulated forward in time, using the  
399  $R_e$  time series and the discretised serial interval for SARS-CoV-2 [36] (see [12]; Web Appendix 11).  
400 These simulated infections are convolved with the observation type-specific delay distribution [38] to  
401 obtain the raw observation time series. In the case of time-varying delay distributions, we assume  
402 the mean of the delay distribution decreases by a fixed amount (1/20) each day, to a minimum of 2  
403 days (e.g. for the confirmed cases this results in a range from 4.5 to 2). When estimating with a  
404 time-varying delay distribution, we draw observations from the true distributions, similar to line list  
405 information recorded by public health authorities. To assess the added value of the deconvolution  
406 method, we compare against a method where we estimate the infection time series by shifting the  
407 observations back by the mean of the delay distribution (termed ‘fixed shift method’).

408 To obtain the final observation time series we can add either weekly or daily sources of noise. In the  
409 case of weekly noise, we reduce the number of cases on the weekend to a fraction  $f$  of the simulated  
410 number, and add the subtracted cases to the following Monday and Tuesday instead. In the case of  
411 daily noise, we add multiplicative Gaussian noise with mean 1 and a set standard deviation on every  
412 day of the time series. If both sources of noise are chosen, the weekly noise is applied first.

**Performance metrics** To quantify the performance of our method on the simulated scenarios, we employ 5 metrics. The normalised root mean square error (RMSE) is given by:

$$1/\bar{R} \sqrt{\frac{1}{N} \sum_{j=1}^N (\hat{R}_j - R_j)^2}, \quad (8)$$

413 where  $\bar{R}$  indicates the mean true  $R_e$ ,  $N$  the length of the time series,  $\hat{R}_j$  the estimated  $R_e$  and  $R_j$  the  
414 true  $R_e$  at time  $j$ . The relative error of the slope of the initial decrease (Slope error) is determined by  
415 comparing the slope of the true and estimated  $R_e$  between the time of the end of the first  $R_e$  plateau  
416 ( $t_e^1$ ) and the start of the second plateau ( $t_s^2$ ). The date of the  $R = 1$  crossing ( $R = 1$  difference)  
417 is determined by the number of days difference between when the true  $R_e$  crosses the threshold  
418 of  $R = 1$  and our  $R_e$  point estimate does so. The fraction of correct above or below 1 estimation  
419 (Correct  $R > 1/R < 1$ ) is determined as the fraction of the time series where we correctly infer that  
420  $R_e$  is significantly above or below 1. Time points where the confidence interval includes values both  
421 above and below 1 are excluded from the calculation. The empirical coverage (Coverage) indicates  
422 the fraction of the time series for which our confidence interval includes the true  $R_e$  value.

#### 423 **4.6 Implementation and method availability**

424 Daily updated results of our method on global COVID-19 data are available online on [https://](https://ibz-shiny.ethz.ch/covid-19-re/)  
425 [ibz-shiny.ethz.ch/covid-19-re/](https://ibz-shiny.ethz.ch/covid-19-re/). The source code of this pipeline is openly accessible (see  
426 <https://github.com/covid-19-Re/dailyR>). We are also continuously updating our data sources,  
427 and welcome anyone who wishes to share quality data for a particular region or country (please  
428 contact the authors, or raise an issue on the Github repository of this project at [https://github.](https://github.com/covid-19-Re/shiny-dailyRe)  
429 [com/covid-19-Re/shiny-dailyRe](https://github.com/covid-19-Re/shiny-dailyRe)).

## 5 References

- [1] Roy Malcolm Anderson and Robert M May. *Infectious diseases of humans : dynamics and control*. Oxford science publications. Oxford University Press, Oxford, 1991.
- [2] Simon Cauchemez, Pierre-Yves Boëlle, Guy Thomas, and Alain-Jacques Valleron. Estimating in real time the efficacy of measures to control emerging communicable diseases. *American journal of epidemiology*, 164(6):591–597, 2006.
- [3] Jacco Wallinga and Marc Lipsitch. How generation intervals shape the relationship between growth rates and reproductive numbers. *Proceedings of the Royal Society B: Biological Sciences*, 274(1609):599–604, 2007.
- [4] Hiroshi Nishiura, Gerardo Chowell, James M. Hyman, Luís M. A. Bettencourt, and Carlos Castillo-Chavez. *The Effective Reproduction Number as a Prelude to Statistical Estimation of Time-Dependent Epidemic Trends*, pages 103–121. Springer Netherlands, Dordrecht, 2009.
- [5] Paul L Delamater, Erica J Street, Timothy F Leslie, Y Tony Yang, and Kathryn H Jacobsen. Complexity of the basic reproduction number ( $r_0$ ). *Emerging infectious diseases*, 25(1):1, 2019.
- [6] Jérémie Scire, Sarah Nadeau, Timothy Vaughan, Gavin Brupbacher, Simon Fuchs, Jürg Sommer, Katrin N. Koch, Reto Misteli, Lukas Mundorff, Thomas Götz, Tobias Eichenberger, Carlos Quinto, Miodrag Savic, Andrea Meienberg, Thilo Burkard, Michael Mayr, Christoph A. Meier, Andreas Widmer, Richard Kuehl, Adrian Egli, Hans H. Hirsch, Stefano Bassetti, Christian H. Nickel, Katharina S. Rentsch, Werner Kübler, Roland Bingisser, Manuel Battegay, Sarah Tschudin-Sutter, and Tanja Stadler. Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. *Swiss medical weekly*, 150(February):w20271, 2020.
- [7] Sheikh Taslim Ali, Lin Wang, Eric HY Lau, Xiao-Ke Xu, Zhanwei Du, Ye Wu, Gabriel M Leung, and Benjamin J Cowling. Serial interval of sars-cov-2 was shortened over time by non-pharmaceutical interventions. *Science*, 369(6507):1106–1109, 2020.
- [8] Seth Flaxman, Swapnil Mishra, Axel Gandy, H. Juliette T. Unwin, Thomas A. Mellan, Helen Coupland, Charles Whittaker, Harrison Zhu, Tresnia Berah, Jeffrey W. Eaton, Mélodie Monod, Pablo N. Perez-Guzman, Nora Schmit, Lucia Cilloni, Kylie E. C. Ainslie, Marc Baguelin, Adhiratha Boonyasiri, Olivia Boyd, Lorenzo Cattarino, Laura V. Cooper, Zulma Cucunubá, Gina Cuomo-Dannenburg, Amy Dighe, Bimandra Djaafara, Iaria Dorigatti, Sabine L. van Elsland, Richard G. FitzJohn, Katy A. M. Gaythorpe, Lily Geidelberg, Nicholas C. Grassly, William D. Green, Timothy Hallett, Arran Hamlet, Wes Hinsley, Ben Jeffrey, Edward Knock, Daniel J. Laydon, Gemma Nedjati-Gilani, Pierre Nouvellet, Kris V. Parag, Igor Siveroni, Hayley A. Thompson, Robert Verity, Erik Volz, Caroline E. Walters, Haowei Wang, Yuanrong Wang, Oliver J. Watson, Peter Winskill, Xiaoyue Xi, Patrick G. T. Walker, Azra C. Ghani, Christl A. Donnelly, Steven Riley, Michaela A. C. Vollmer, Neil M. Ferguson, Lucy C. Okell, Samir Bhatt, and Imperial College COVID-19 Response Team. Estimating the effects of non-pharmaceutical interventions on covid-19 in europe. *Nature*, 584(7820):257–261, 2020.
- [9] Adam J Kucharski, Timothy W Russell, Charlie Diamond, Yang Liu, John Edmunds, Sebastian Funk, Rosalind M Eggo, Fiona Sun, Mark Jit, James D Munday, et al. Early dynamics of transmission and control of covid-19: a mathematical modelling study. *The lancet infectious diseases*, 2020.
- [10] Tao Zhou, Quanhui Liu, Zimo Yang, Jingyi Liao, Kexin Yang, Wei Bai, Xin Lu, and Wei Zhang. Preliminary prediction of the basic reproduction number of the wuhan novel coronavirus 2019-ncov. *Journal of Evidence-Based Medicine*, 13(1):3–7, 2020.
- [11] Jacco Wallinga and Peter Teunis. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. *American Journal of epidemiology*, 160(6):509–516, 2004.



- [12] Anne Cori, Neil M. Ferguson, Christophe Fraser, and Simon Cauchemez. A new framework and software to estimate time-varying reproduction numbers during epidemics. *American Journal of Epidemiology*, 178(9):1505–1512, 2013.
- [13] Katelyn M Gostic, Lauren McGough, Edward Baskerville, Sam Abbott, Keya Joshi, Christine Tedijanto, Rebecca Kahn, Rene Niehus, James A Hay, Pablo M. De Salazar, Joel Hellewell, Sophie Meakin, James Munday, Nikos Bosse, Katharine Sherratt, Robin M Thompson, Laura F White, Jana Huisman, Jérémie Scire, Sebastian Bonhoeffer, Tanja Stadler, Jacco Wallinga, Sebastian Funk, Marc Lipsitch, and Sarah Cobey. Practical considerations for measuring the effective reproductive number, Rt. *medRxiv*, page 2020.06.18.20134858, 2020.
- [14] Edward Goldstein, Jonathan Dushoff, Ma Junling, Joshua B. Plotkin, David J.D. Earn, and Marc Lipsitch. Reconstructing influenza incidence by deconvolution of daily mortality time series. *Proceedings of the National Academy of Sciences of the United States of America*, 106(51):21825–21829, 2009.
- [15] Daniel Wyler and Markus Petermann. A pitfall in estimating the effective reproductive number Rt for COVID-19. *Swiss Medical Weekly*, 150(2930), 2020.
- [16] S Abbott, J Hellewell, RN Thompson, K Sherratt, HP Gibbs, NI Bosse, JD Munday, S Meakin, EL Doughty, JY Chun, YWD Chan, F Finger, P Campbell, A Endo, CAB Pearson, A Gimma, T Russell, null null, S Flasche, AJ Kucharski, RM Eggo, and S Funk. Estimating the time-varying reproduction number of sars-cov-2 using national and subnational case counts [version 1; peer review: awaiting peer review]. *Wellcome Open Research*, 5(112), 2020.
- [17] Kevin Systrom, Thomas Vladek, and Mike Krieger. Project title. <https://github.com/rtcovidlive/covid-model>, 2020.
- [18] Cristian Tebé, Joan Valls, Pau Satorra, and Aurelio Tobías. Covid19-world: a shiny application to perform comprehensive country-specific data visualization for sars-cov-2 epidemic. *BMC Medical Research Methodology*, 20(1):1–7, 2020.
- [19] An Pan, Li Liu, Chaolong Wang, Huan Guo, Xingjie Hao, Qi Wang, Jiao Huang, Na He, Hongjie Yu, Xihong Lin, et al. Association of public health interventions with the epidemiology of the covid-19 outbreak in wuhan, china. *Jama*, 323(19):1915–1923, 2020.
- [20] Robert Koch Institut. *Täglicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19)*, 2020 (accessed November 16, 2020).
- [21] Thomas Obadia, Romana Haneef, and Pierre-Yves Boëlle. The r0 package: a toolbox to estimate reproduction numbers for epidemic outbreaks. *BMC medical informatics and decision making*, 12(1):1–9, 2012.
- [22] Rachel T Esra, Lise Jamesion, Matthew P Fox, Daniel Letswalo, Nkosinathi Ngcobo, Sithabile Mngadi, Janne Global Estill, Gesine Meyer-Rath, and Olivia Keiser. Evaluating the impact of non-pharmaceutical interventions for sars-cov-2 on a global scale. *medRxiv*, 2020.
- [23] Nicolas Banholzer, Eva van Weenen, Bernhard Kratzwald, Arne Seeliger, Daniel Tschernutter, Pierluigi Bottrighi, Alberto Cenedese, Joan Puig Salles, Stefan Feuerriegel, and Werner Vach. Estimating the impact of non-pharmaceutical interventions on documented infections with covid-19: A cross-country analysis. *medRxiv*, 2020.
- [24] Kristian Soltesz, Fredrik Gustafsson, Toomas Timpka, Joakim Jaldén, Carl Jidling, Albin Heimerson, Thomas Schön, Armin Spreco, Joakim Ekberg, Örjan Dahlström, et al. Sensitivity analysis of the effects of non-pharmaceutical interventions on covid-19 in europe. *medRxiv*, 2020.
- [25] Nils Haug, Lukas Geyrhofer, Alessandro Londei, Elma Dervic, Amelie Desvars-Larrive, Vittorio Loreto, Beate Piniór, Stefan Thurner, and Peter Klimek. Ranking the effectiveness of worldwide covid-19 government interventions. *MedRxiv*, 2020.

- [26] Ilija Kohanovski, Uri Obolski, and Yoav Ram. Inferring the effective start dates of non-pharmaceutical interventions during covid-19 outbreaks. *medRxiv*, 2020.
- [27] Mrinank Sharma, Sören Mindermann, Jan Markus Brauner, Gavin Leech, Anna B Stephenson, Tomáš Gavenčiak, Jan Kulveit, Yee Whye Teh, Leonid Chindelevitch, and Yarin Gal. On the robustness of effectiveness estimation of nonpharmaceutical interventions against covid-19 transmission. *arXiv preprint arXiv:2007.13454*, 2020.
- [28] JC Lemaitre, J Perez-Saez, AS Azman, A Rinaldo, and J Fellay. Assessing the impact of non-pharmaceutical interventions on sars-cov-2 transmission in switzerland. *Swiss Medical Weekly*, 150:w20295–w20295, 2020.
- [29] Thomas Hale, Sam Webster, Anna Petherick, Toby Phillips, and Beatriz Kira. *Oxford COVID-19 Government Response Tracker*. Blavatnik School of Government, 2020.
- [30] Abiel Sebhatu, Karl Wennberg, Stefan Arora-Jonsson, and Staffan I Lindberg. Explaining the homogeneous diffusion of covid-19 nonpharmaceutical interventions across heterogeneous countries. *Proceedings of the National Academy of Sciences*, 117(35):21201–21208, 2020.
- [31] Sascha Karberg. *Der "überflüssige" Lockdown?* Tagesspiegel, 2020 (accessed October 22, 2020).
- [32] Moustapha Mbow, Bertrand Lell, Simon P Jochems, Badara Cisse, Souleymane Mboup, Benjamin G Dewals, Assan Jaye, Alioune Dieye, and Maria Yazdanbakhsh. Covid-19 in africa: Dampening the storm? *Science*, 369(6504):624–626, 2020.
- [33] Dylan H Morris, Kwe Claude H Yinda, Amandine Gamble, Fernando W Rossine, Qishen Huang, Trenton Bushmaker, Robert J Fischer, M Jeremiah Matson, Neeltje van Doremalen, Peter J Vikesland, et al. The effect of temperature and humidity on the stability of sars-cov-2 and other enveloped viruses. *bioRxiv*, 2020.
- [34] John M Chambers. *Statistical models in S*. Wadsworth & Brooks/Cole computer science series. Wadsworth & Brooks/Cole Advanced Books & Software, Pacific Grove, California, 1992.
- [35] European Centre for Disease Prevention and Control (ECDC). Daily number of new reported cases of covid-19 by country worldwide. <https://opendata.ecdc.europa.eu/covid19/casedistribution/csv>. Accessed: 2020-10-02.
- [36] Hiroshi Nishiura, Natalie M. Linton, and Andrei R. Akhmetzhanov. Serial interval of novel coronavirus (COVID-19) infections. *International Journal of Infectious Diseases*, 93:284–286, apr 2020.
- [37] John M Griffin, Aine B Collins, Kevin Hunt, David McEvoy, Miriam Casey, Andrew W Byrne, Conor G McAloon, Ann Barber, Elizabeth Ann Lane, and Simon J More. A rapid review of available evidence on the serial interval and generation time of covid-19. *medRxiv*, 2020.
- [38] Natalie M. Linton, Tetsuro Kobayashi, Yichi Yang, Katsuma Hayashi, Andrei R. Akhmetzhanov, Sung-mok Jung, Baoyin Yuan, Ryo Kinoshita, and Hiroshi Nishiura. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *Journal of Clinical Medicine*, 9(2):538, feb 2020.
- [39] Qifang Bi, Yongsheng Wu, Shujiang Mei, Chenfei Ye, Xuan Zou, Zhen Zhang, Xiaojian Liu, Lan Wei, Shaun A Truelove, Tong Zhang, et al. Epidemiology and transmission of covid-19 in 391 cases and 1286 of their close contacts in shenzhen, china: a retrospective cohort study. *The Lancet Infectious Diseases*, 2020.
- [40] Lorenzo Pellis, Francesca Scarabel, Helena B Stage, Christopher E Overton, Lauren HK Chappell, Katrina A Lythgoe, Elizabeth Fearon, Emma Bennett, Jacob Curran-Sebastian, Rajenki

Das, et al. Challenges in control of covid-19: short doubling time and long delay to effect of interventions. *arXiv preprint arXiv:2004.00117*, 2020.

- [41] Esteban Ortiz-Ospina Max Roser, Hannah Ritchie and Joe Hasell. Coronavirus pandemic (covid-19). *Our World in Data*, 2020. <https://ourworldindata.org/coronavirus>.
- [42] Gideon Meyerowitz-Katz and Lea Merone. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. *International Journal of Infectious Diseases*, Oct 2020.
- [43] Anthony Hauser, Michel J. Counotte, Charles C. Margossian, Garyfallos Konstantinoudis, Nicola Low, Christian L. Althaus, and Julien Riou. Estimation of sars-cov-2 mortality during the early stages of an epidemic: A modeling study in hubei, china, and six regions in europe. *PLOS Medicine*, 17(7):1–17, 07 2020.
- [44] Albert Esteve, Iñaki Permanyer, Diederik Boertien, and James W. Vaupel. National age and coresidence patterns shape covid-19 vulnerability. *Proceedings of the National Academy of Sciences*, 117(28):16118–16120, 2020.
- [45] Wan Yang, Sasikiran Kandula, Mary Huynh, Sharon K Greene, Gretchen Van Wye, Wenhui Li, Hiu Tai Chan, Emily McGibbon, Alice Yeung, Don Olson, Anne Fine, and Jeffrey Shaman. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet Infectious Diseases*, Oct 2020.
- [46] Raphael Minder. *Counting Bodies and Pointing Fingers as Spain Tallies Coronavirus Dead*. New York Times, 2020 (accessed October 22, 2020).
- [47] James O Lloyd-Smith, Sebastian J Schreiber, P Ekkehard Kopp, and Wayne M Getz. Super-spreading and the effect of individual variation on disease emergence. *Nature*, 438(7066):355–359, 2005.

## 6 Supplementary Discussion

### 6.1 Observation types and the influence of testing

430 Here, we briefly discuss the benefits and potential biases of the three types of observations we used.  
431 The most commonly used proxy for infection incidence is the incidence of confirmed cases. It is the  
432 least indirect way of observing infection events. However, it generally assumes that (i) the proportion  
433 of infected individuals that is tested, and (ii) the distribution of the delay between infection and testing  
434 are constant through time. Unfortunately, these assumptions do not generally hold.  
435

436 As long as the sampling proportion is constant throughout the considered time period, the  $R_e$  esti-  
437 mates of EpiEstim are not affected by under-sampling [12]. During the SARS-CoV-2 epidemic, many  
438 countries initially restricted testing to only severe cases, before switching to a more extensive testing  
439 effort after curbing the first epidemic wave and ramping up testing capacity [41]. Changes in testing  
440 strategy as well as bottlenecks in testing capacity result in a varying fraction of infected individuals  
441 that are confirmed positive, but also in the delay between infection and test confirmation. This can  
442 bias the  $R_e$  estimate, as it will attribute an increase/decrease in case numbers between consecutive  
443 time points to a change in infection incidence, rather than a change in testing.

444 However, it is important to note that the ‘memory’ inherent in the  $R_e$  estimate is dictated by the serial  
445 interval  $w_s$ . An event at time  $t$  which changes the proportion of true infection incidence observed  
446 per day, e.g. a change in testing policy, will bias the  $R_e$  estimate for the number of days needed to  
447 reach the 95% of  $w_s$  (compare Materials and Methods, equation 1). We do not observe the infection  
448 incidence directly, but if the deconvolution is assumed to be perfect, the intuition for the number of  
449 days of biased  $R_e$  estimates still holds.

450 It is further possible to investigate the influence of testing intensity, by applying the  $R_e$  estimation  
451 method separately to a case incidence time series which is adjusted for the intensity of the testing  
452 effort. We have added this analysis to our online dashboard (where we show the number of confirmed  
453 cases / number of tests, normalised by the mean number of tests). However, one should note that  
454 such a normalisation does not take into account that the probability of test positivity might also  
455 change with the number of tests (e.g. by prioritising likely cases at low numbers of tests).

456 In contrast, the incidence of hospital admittance and deaths are likely based primarily on the severity  
457 of the symptoms, and mostly unaffected by changes in testing strategies, or the magnitude of the  
458 epidemic. This makes them valuable complementary observations of infection events [14]. However,  
459 also here biases can occur. First, only a small fraction of all infections results in hospitalisation or  
460 death (a recent meta-analysis found an average infection fatality ratio for SARS-CoV-2 of 0.68% [42]).  
461 This fraction varies with the risk group of the infected population [42, 43, 44, 45], introducing potential  
462 biases in  $R_e$  estimations when outbreaks occur in particularly age-stratified settings. Second, if a  
463 country’s health infrastructure becomes overburdened and hospitals are forced to triage or delay  
464 admission, we expect the fraction of hospital admissions to decrease, and deaths to increase. Third,  
465 the likelihood to die from an infection may change through time as new treatment strategies are  
466 developed. Additionally, guidelines used to record COVID-19 as the cause of death have changed  
467 through time for some countries [46]. Lastly, the delay between infection and hospitalisation or death  
468 is expected to be longer than the delay until case confirmation, with the result that these  $R_e$  estimates  
469 are less timely. One should note that these observation type specific biases could also be seen as  
470 a source of information. The types simply describe a different epidemic if very structured population  
471 with highly different mortality rates are captured (e.g. elderly homes).

## 472 6.2 Method Limitations

473 The  $R_e$  estimation method we present in the main text relies on several assumptions. Here we  
474 highlight the limitations that occur when these assumptions are violated.

475 First, the geographical scale of the  $R_e$  estimates is determined by the incidence data itself. The  
476  $R_e$  calculated for a country represents an average, summarised across multiple local epidemics  
477 unfolding in different regions.  $R_e$  values need not be identical in different local epidemics across a  
478 country or administrative region. In particular, in times of very low pathogen transmission, single  
479 super-spreading events can significantly increase the estimated  $R_e$  of the entire country [47].

480 Second, in our deconvolution step we account for an incubation period and a delay from symptom  
481 onset to case observation. Implicitly, we thus assume that all reported cases come from symptomatic  
482 individuals. This is certainly true for hospitalised and deceased patients, but does not have to hold for  
483 all confirmed cases. Similar to the testing intensity (discussed in Section 6.1), this would not bias our  
484 estimates as long as the fraction of asymptomatic or presymptomatic individuals is constant through  
485 time. However, the fraction of asymptomatic individuals could vary with the population structure  
486 and age-stratification. The fraction of tested presymptomatic individuals could vary with the testing  
487 strategy and the intensity of the testing effort.

488 Third, in our current analysis we assume a single serial interval distribution for all geographic lo-  
489 cations and all times. However, behaviour, population contact structure, and cultural differences in  
490 dealing with infection symptoms, will cause geographic and temporal variations in the serial interval.  
491 In particular, the implementation of non-pharmaceutical interventions can significantly shorten the  
492 serial interval [7]. Misspecification of the generation interval will be most pronounced for  $R_e$  values  
493 further away from one [13].

494 Lastly, our estimates of the effective reproductive number  $R_e$  are subject to changes in data reporting.  
495 There are frequent changes in the way in which public health offices update their observed incidence  
496 data: the amount of variables shared (e.g. Brasil, the UK excluded testing information), their fre-  
497 quency (e.g. Swiss cantons moved to weekly data updates when daily numbers became low), the  
498 amount of consolidation (i.e. how much values reported for a given day change in subsequent days),  
499 and what constitutes a COVID-19 case [46]. These variables have all changed during the epidemic,  
500 frequently in response to political pressure or the magnitude of the local epidemic and the resulting  
501 workload at the public health offices [46]. This affects the timeliness of our estimates, and can cause  
502 the estimated  $R_e$  to change a bit between days.

## 503 7 Supplementary Methods

504 **Discretisation of delay distributions** When approximating delay distributions by gamma distribu-  
505 tions, we discretise these in the following fashion:


$$m_l = \begin{cases} \int_0^{0.5} f(x) dx & l = 0 \\ \int_{l-0.5}^{l+0.5} f(x) dx & l \in \mathbb{N}^*, \end{cases} \quad (9)$$

506 where  $f$  is either the probability density function (p.d.f) of the gamma-distributed delay distribution,  
507 or the p.d.f of the sum of two independent gamma-distributed delay distributions. The former applies  
508 when line list data is available, and the observed data is deconvolved with the gamma-distributed  
509 incubation period separately from the empirical delay distribution of symptom onset to observation.  
510 The latter applies whenever the observed case data is jointly deconvolved with the incubation period  
511 and delay between symptom onset and observation.


512 Because the probability density function of a sum of two independent gamma distributions does not  
513 admit a simple form in the general case, in practice we approximate the p.d.f by drawing a million  
514 independent pairs of samples, one from each gamma distribution, summing the pairs, and computing  
515 the empirical cumulative distribution function of the sampled distribution.

## 516 8 Supplementary Materials

### 517 8.1 Supplementary Simulations




**Figure S1: Performance of our method on simulated scenarios with noise and without smoothing.** The  $R_1$  (point shape),  $t_3$  (point colour), and  $I_0$  were varied, all other parameters kept constant (see Materials and Methods 4.5). Three plateaus were used, with  $R_2 = 0.5$ ,  $R_3 = 1.2$ . The columns indicate different combinations noise: weekly noise ('week') reduces the number of cases on the weekend to a fraction  $f$  and redistributes these to Monday and Tuesday ( $f = 1$  is the weakest noise), and daily noise ('norm') which refers to multiplicative Gaussian noise with mean 1 and a set standard deviation  $sd$  on every day of the time series ( $sd = 0$  is weakest).




**Figure S2: Performance of our method on simulated scenarios with noise and with smoothing.** The  $R_1$  (point shape),  $t_3$  (point colour), and  $I_0$  were varied, all other parameters kept constant (see Methods 4.5). Three plateaus were used, with  $R_2 = 0.5$ ,  $R_3 = 1.2$ . The columns indicate different combinations noise: weekly noise ('week') reduces the number of cases on the weekend to a fraction  $f$  and redistributes these to Monday and Tuesday ( $f = 1$  is the weakest noise), and daily noise ('norm') which refers to multiplicative Gaussian noise with mean 1 and a set standard deviation  $sd$  on every day of the time series ( $sd = 0$  is weakest).

(a) Confirmed cases






(b) Deaths




**Figure S3: Performance of our method on simulated scenarios with misspecified delay distributions.** We changed the mean of the delay distribution (5.5 for symptom-onset to case confirmation, 15.0 for symptom-onset to death) by the numbers above the columns. The  $R_1$  (point shape),  $t_3$  (point colour), and  $I_0$  were varied, all other parameters kept constant (see Materials and Methods 4.5). The observations were smoothed and no noise was added. Three plateaus were used, with  $R_2 = 0.5$ ,  $R_3 = 1.2$ . No noise was added to the observations.


(a) Confirmed cases



(b) Deaths




**Figure S4: Performance of our method on simulated scenarios with time-varying delay distributions.** The observations were simulated with time-varying delay distributions (see Materials and Methods, section on simulations), and then estimated with (right column) or without (left column) taking the time-varying distributions into account. The  $R_1$  (point shape),  $t_3$  (point colour), and  $I_0$  were varied, all other parameters kept constant. The observations were smoothed and no noise was added. Three plateaus were used, with  $R_2 = 0.5$ ,  $R_3 = 1.2$ .




**Figure S5: Performance of our method on simulated scenarios using the fixed shift (TRUE) instead of the deconvolution (FALSE) to infer infection incidence.** In case of the fixed shift method the observations are shifted back by the mean of the delay distribution. For both methods the observations are bootstrapped in the same way, leading to similar width of the confidence intervals. The  $R_1$  (point shape),  $t_3$  (point colour), and  $I_0$  were varied, all other parameters kept constant (see Materials and Methods 4.5). The observations were smoothed and no noise was added. Three plateaus were used, with  $R_2 = 0.5$ ,  $R_3 = 1.2$ .

## 518 8.2 Switzerland specific results




**Figure S6: Mean delay in Switzerland between onset of symptoms and reporting.** For each date, the mean is taken over the last 300 reports with known symptom onset date, based on line list data from the FOPH. For early dates, before 300 reports are available, the mean is taken over the first 300 reports.



**Figure S7: Comparison of effective reproductive number estimates with or without accounting for known symptom onset dates and for time-variability on reporting delays.** The comparison is based on time series of confirmed cases in Switzerland, from line list data provided by the FOPH. Both the inclusion of known symptom onset dates and of the time-variability of reporting delay distributions have an effect on the  $R_e$  estimates, in particular for early estimates in this case.

## 519 8.3 $R = 1$ crossings



**Figure S8: Effective reproductive number estimates with or without accounting for known imports.** The comparison is based on time series of confirmed cases in Switzerland, from line list data provided by the FOPH. The analysis without imports is unbiased if the number of imports equals the number of exports. Since the analysis accounting for imports is not accounting for exports, the results are a lower limit for the effective reproductive number.

Country	Lockdown	R=1 based on Confirmed cases	R=1 based on Deaths	R=1 based on Hospitalisations
Austria	16-03	21-03 [21-03, 22-03]		
Belgium	18-03	31-03 [30-03, 02-04]	26-03 [25-03, 28-03]	25-03 [24-03, 26-03]
Denmark	18-03	<b>≤10-03 [≤10-03, 11-03]</b>	23-03 [20-03, ≥19-09]	
Finland	16-03	03-04 [01-04, 06-04]	08-04 [26-03, 13-04]	
France	17-03	27-03 [27-03, 28-03]	24-03 [23-03, 24-03]	26-03 [26-03, 27-03]
Germany	22-03	26-03 [26-03, 27-03]	02-04 [29-03, 04-04]	
Ireland	27-03	09-04 [08-04, 10-04]	09-04 [07-04, 12-04]	
Italy	10-03	18-03 [18-03, 19-03]	14-03 [13-03, 15-03]	
Netherlands	23-03	01-04 [26-03, 04-04]	<b>20-03 [18-03, 23-03]</b>	
Norway	14-03	23-03 [22-03, 24-03]	28-03 [17-03, 11-04]	
Poland	25-03	03-04 [02-04, 17-04]	10-04 [ <b>25-03</b> , ≥19-09]	
Portugal	16-03	29-03 [28-03, 30-03]	29-03 [23-03, 11-04]	
Romania	24-03	06-04 [02-04, 30-04]	30-03 [26-03, 01-05]	
Russian Federation	30-03	05-05 [04-05, 05-05]	19-05 [17-04, 04-06]	
Slovenia	20-03	24-03 [ <b>≤14-03, 28-03]</b>	26-03 [22-03, ≥19-09]	
Spain	14-03	18-03 [02-02, 18-03]		
Sweden	-	<b>19-04 [01-04, 21-04]</b>	<b>29-03 [26-03, 06-04]</b>	
Switzerland	17-03	22-03 [21-03, 22-03]	21-03 [19-03, 24-03]	17-03 [ <b>16-03, 19-03]</b>
Turkey	21-03	09-04 [08-04, 09-04]	05-04 [01-04, 08-04]	
United Kingdom	24-03	31-03 [30-03, 31-03]	25-03 [25-03, 26-03]	29-03 [28-03, 29-03]

**Table S1: The date that  $R_e < 1$  for the first time.** Based on news reports, we determined when a country implemented stay-at-home orders (a 'lockdown'). Using our method we determined when the  $R_e$  estimate and its confidence intervals first dropped below 1. Based on our  $R_e$  estimates for confirmed cases, only two countries that implemented a nationwide lockdown (Denmark, Slovenia) had confidence intervals that included or were below one before a nationwide lockdown was implemented. For  $R_e$  estimates based on COVID-19 deaths, there are also two, but different ones (the Netherlands, Poland).

Country	First Measure	Lockdown URL
Austria	10-03	<a href="https://mrc-ide.github.io/covid19estimates/#/interventions">https://mrc-ide.github.io/covid19estimates/#/interventions</a>
Belgium	10-03	<a href="https://mrc-ide.github.io/covid19estimates/#/interventions">https://mrc-ide.github.io/covid19estimates/#/interventions</a>
Denmark	12-03	<a href="https://mrc-ide.github.io/covid19estimates/#/interventions">https://mrc-ide.github.io/covid19estimates/#/interventions</a>
Finland	16-03	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Finland#Response_by_sector">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Finland#Response_by_sector</a>
France	29-02	<a href="https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/">https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/</a>
Germany	06-03	<a href="https://www.bundesregierung.de/breg-de/themen/coronavirus/besprechung-der-bundeskanzlerin-mit-den-regierungschefinnen-und-regierungschefen-der">https://www.bundesregierung.de/breg-de/themen/coronavirus/besprechung-der-bundeskanzlerin-mit-den-regierungschefinnen-und-regierungschefen-der</a>
Ireland	12-03	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_the_Republic_of_Ireland#Containment_phase">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_the_Republic_of_Ireland#Containment_phase</a>
Italy	22-02	<a href="https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/">https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/</a>
Netherlands	10-03	<a href="https://www.volkskrant.nl/nieuws-achtergrond/bijeenkomsten-tot-1-juni-verboden-burgemeesters-mogen-handhaven-met-forse-boetes-voor-perpetu">https://www.volkskrant.nl/nieuws-achtergrond/bijeenkomsten-tot-1-juni-verboden-burgemeesters-mogen-handhaven-met-forse-boetes-voor-perpetu</a>
Norway	12-03	<a href="https://www.euractiv.com/section/coronavirus/short_news/norway-update-covid-19/">https://www.euractiv.com/section/coronavirus/short_news/norway-update-covid-19/</a>
Poland	09-03	<a href="https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/">https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/</a>
Portugal	11-03	<a href="https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/">https://www.politico.eu/article/europes-coronavirus-lockdown-measures-compared/</a>
Romania	21-02	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Romania">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Romania</a>
Russian Federation	25-03	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Russia">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Russia</a>
Slovenia	09-03	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Slovenia">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Slovenia</a>
Spain	10-03	<a href="https://www.elmundo.es/espana/2020/03/13/5e6b844e21efa0dd258b45a5.html">https://www.elmundo.es/espana/2020/03/13/5e6b844e21efa0dd258b45a5.html</a>
Sweden	11-03	
Switzerland	28-02	<a href="https://www.bbc.com/news/uk-52012432">https://www.bbc.com/news/uk-52012432</a>
Turkey	12-03	<a href="https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Turkey#Government_response">https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Turkey#Government_response</a>
United Kingdom	12-03	<a href="https://www.bbc.com/news/uk-52012432">https://www.bbc.com/news/uk-52012432</a>

**Table S2:** News and public resources used to determine when a country implemented the first non-pharmaceutical interventions, and a nationwide lockdown.

520 **SI 50 analysis** Reference date: first day the stringency index exceeded 50 ( $SI > 50$ ).

521 The 39 included countries: Algeria, Andorra(\*), Australia, Austria, Bahrain, Belgium, Brazil, Canada,  
522 Chile, China, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Iceland, India, Indonesia,  
523 Iran, Ireland(\*), South Korea(\*), Malaysia, Mexico, Netherlands, Norway, Portugal, Qatar, Singapore,  
524 Slovenia, Spain, Switzerland, Tajikistan, Thailand, United Arab Emirates, United Kingdom, United  
525 States of America, Vietnam.

526 The star indicates the country was not included in the  $\Delta SI$  analysis.


527 For 34/39 countries the  $R_e$  estimate was above one prior to the reference date, and significantly so  
528 for 28/39. The countries that reached  $R_e < 1$  prior to the reference date were Andorra (15 days  
529 prior), Australia (1 day prior), Denmark (3 days prior), Qatar (5 days prior), and Vietnam (2 days  
530 prior).

531  **$\Delta SI$  analysis** Reference date: date of the biggest 7-day increase in the SI.

532 The 50 included countries: Algeria, Australia, Austria, Bahrain, Belarus(\*), Belgium, Brazil, Canada,  
533 Chile, China, Colombia(\*), Croatia(\*), Czech Republic(\*), Denmark, Egypt, Estonia, Finland, France,  
534 Germany, Greece, Iceland, India, Indonesia, Iran, Israel(\*), Japan(\*), Lebanon(\*), Malaysia, Mexico,  
535 Netherlands, New Zealand(\*), Norway, Pakistan(\*), Philippines(\*), Portugal, Qatar, Russia(\*), Ser-  
536 bia(\*), Singapore, Slovenia, Spain, Sweden(\*), Switzerland, Tajikistan, Thailand, Turkey(\*), United  
537 Arab Emirates, United Kingdom, United States of America, Vietnam.

538 The star indicates the country was not included in the  $SI_{50}$  analysis.

539 For 44/50 countries the  $R_e$  estimate was above one prior to the reference date, and significantly so  
540 for 36/50. The countries that reached  $R_e < 1$  prior to the reference date were Australia (2 days prior),  
541 Denmark (4 days prior), New Zealand (2 days prior), Qatar (6 days prior), Tajikistan (17 days prior),  
542 and Vietnam (9 days prior).




**Figure S9: The association between non-pharmaceutical interventions and  $R_e$ .** Relation between the slope of the  $R_e$  estimates on  $t_{SI50}$  and the increase in the stringency index in the 7 days prior to  $t_{SI50}$ . Countries are indicated by their ISO3 country code, colours represent continents.


543 **8.4 Implementation/Lifting of individual NPIs**

544 **8.5 Sensitivity of the deconvolution to initial conditions**





**Figure S10: The time between the start of lockdown and  $R < 1$ .** (a) The stringency index on the day of lockdown is not a good predictor for the number of days it will take for  $R_e < 1$  ( $p = 0.9$ ). (b) The  $R_e$  estimate on the day of lockdown is significantly associated with the number of days it will take for  $R_e < 1$  ( $p = 0.03$ , adjusted  $R^2 = 0.2$ ). The regression analysis used the  $R_e$  point estimate for each country. The uncertainties shown in the plot were not used for this analysis. Countries are the same as in table 1, and indicated by their ISO3 country code.




**Figure S11: The relation between the stringency and minimum  $R_e$  attained during lockdown in Europe.** This trend is not significant ( $p = 0.14$ ). Lockdown here refers to the period of constant, maximum stringency during the first wave in Europe (April 2020). There is substantial variation in the duration of the lockdown, and the number of days after the start of the lockdown that the minimum  $R_e$  was reached. The regression analysis used the  $R_e$  point estimate for each country. The uncertainties shown in the plot were not used for this analysis. Countries are the same as in table 1, and indicated by their ISO3 country code.

Intervention index	P-value < 0.05/48	P-value 0.05/48 < p < 0.05
C1: School closing	Europe	Africa, Asia, Oceania
C2: Workplace closing		Asia, Europe
C3: Cancel public events	South America	Asia
C4: Restriction on gatherings		Asia, Europe
C5: Close public transport	Europe	North America
C6: Stay at home requirements	North America	Europe, Oceania
C7: Restrictions on internal movement		North America, Asia, Europe
C8: International travel controls		Europe

**Table S3: Continents for which an increase in stringency was significantly more associated with a subsequent reduction in  $R_e$  than a reduction in stringency.** Significance was determined by permutation test for each index separately, with significance threshold  $\alpha = 0.05$ , and corrected for 48-way hypothesis testing.


Intervention index	P-value < 0.05/48	P-value 0.05/48 < p < 0.05
C1: School closing	Europe ( $R^2 = 0.13$ )	Asia ( $R^2 < 0.1$ )
C2: Workplace closing	Europe ( $R^2 < 0.1$ )	Asia ( $R^2 < 0.1$ )
C3: Cancel public events	South America ( $R^2 = 0.77$ )	Asia ( $R^2 < 0.1$ )
C4: Restriction on gatherings	Europe ( $R^2 < 0.1$ )	
C5: Close public transport	Europe ( $R^2 = 0.17$ )	
C6: Stay at home requirements	Europe ( $R^2 < 0.1$ )	North America ( $R^2 = 0.15$ )
C7: Restrictions on internal movement	Europe ( $R^2 < 0.1$ )	North America ( $R^2 = 0.13$ ), Asia ( $R^2 < 0.1$ )
C8: International travel controls		Europe ( $R^2 < 0.1$ )


**Table S4: Continents where the estimated one-week change in  $R_e$  is significantly determined by changes in individual stringency indices.** Significance was determined with significance threshold  $\alpha = 0.05$ , and corrected for 48-way hypothesis testing.



**Figure S12: The one-week change in  $R_e$  following changes in government stringency.** The rows C1-C8 refer to different stringency indices (see table S4).

(a) Whole timeseries





**Figure S13:** Assessing the sensitivity of the deconvolution to different initial estimates. Panel (b) shows the last fortnight of panel (a). Confidence intervals are computed on 20 bootstraps of the original time series. The columns represent a shift by 10 days, 8 days, or the mode of the delay distribution (7 days). The rows show ten countries in our dataset. It is clear that augmenting both ends with zeros can lead to spurious increases in incidence towards the present (blue curves). Augmenting with a constant non-zero integer (purple), forecasting with an ARIMA model (green), and forecasting with an exponential model (yellow), all perform similarly.